HelicoAnonymous Auckland, New Zealand-based biopharma company, raised AUD $1.8M in Seed funding.
TheRound was led By Icehouse VenturesParticipation from Custos Privatestiftung, David Ross.
The company intends to use the funds to extend R&D and staff numbers.
LedCEO Ilya Vensky, HelicoIt is developing a proprietary computational platform that allows synthetic biology research to be conducted using AI-based prediction and modeling tools. TheLong-term goal is to create a seed bank of drugs that can be licensed to grow medical supplies. inYou can have confined greenhouses anywhere inThe world.
TheCompany is based in the new, deep-tech facility Outset Ventures in Auckland. TheFacility has GMO-certified laboratories and HelicoHas gained New Zealand Environmental Protection Authority approval for R&D using genetically modified organisms.
FinSMEs
18/05/2022
